comparemela.com

Latest Breaking News On - Key pre specified secondary endpoints - Page 1 : comparemela.com

Ascendis Pharma A/S Announces Phase 3 PaTHway Trial of TransCon™ PTH in Adults with Hypoparathyroidism Met Primary and All Key Secondary Endpoints

– For the primary composite endpoint, TransCon PTH demonstrated a response rate of 78.7% compared to 4.8% for control . – TransCon PTH demonstrated statistically. | March 13, 2022

United statesNew jerseyPalo altoRedwood cityBaden wübergAimee shuAscendis pharmaMelinda bakerTim leeOutcomes trust incAscendis pharma groupDial in internationalPatti bankAscendis pharma hp patient experience researchExchange commissionUs food drug administration for transcon

Ascendis Pharma A/S Announces Phase 3 PaTHway Trial of

– For the primary composite endpoint, TransCon PTH demonstrated a response rate of 78.7% compared to 4.8% for control (p-value <0.0001). – TransCon.

United statesNew jerseyPalo altoRedwood cityBaden wübergAimee shuAscendis pharmaOutcomes trust incAscendis pharma groupDial in internationalAscendis pharma hp patient experience researchExchange commissionUs food drug administration for transconEuropean unionEuropean medicines agencyClinical development

vimarsana © 2020. All Rights Reserved.